FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)’s KT-621 for Eosinophilic Asthma

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Kymera Therapeutics, Inc. is among the ...
Healio

FDA grants fast track designation to KT-621 for moderate to severe eosinophilic asthma

The FDA granted fast track designation to KT-621 for treating patients with moderate to severe eosinophilic asthma, according ...
MPR

FDA Fast Tracks Intra-Articular GLP-1RA for Knee Osteoarthritis

By targeting underlying synovitis, the novel intra-articular liraglutide formulation 4P004 aims to bridge the gap between transient symptom relief and disease modification in knee OA.

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and ...

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation ...

GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...
WFXG

4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis

FDA Fast Track Designation granted to 4P004 for the treatment of knee osteoarthritis, recognizing the disease as a ...
Targeted Oncology

FDA Grants Fast Track Designation to BBO-11818 in KRAS-Mutant PDAC

FDA fast track designation supports expedited development and regulatory interaction for BBO-11818 in advanced KRAS-mutant ...
Yahoo

Affinia receives FDA fast track designation for AFTX-201

Add Yahoo as a preferred source to see more of our stories on Google. The therapy is being evaluated in the ongoing Phase I/II UPBEAT clinical trial in BAG3 DCM patients. Credit: NMK-Studio / ...